Johnson & Johnson announced it will present 16 studies at the European Society for Medical Oncology (ESMO) 2025 Congress, focusing on progress in treatments for solid tumors such as head and neck, lung, bladder, and prostate cancers. The presentations reflect the company's focus on developing new therapies for some of the most difficult and underserved cancer types.
Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine, stated, “We’ve entered a new era for Johnson & Johnson in oncology, delivering the latest bold advances in solid tumors. We’re advancing the next generation of treatments and resetting expectations across bladder, prostate, colorectal, head and neck and EGFR-mutated lung cancer.”
“These results highlight the promise of our innovation, from novel mechanisms that harness the immune system to organ-preserving approaches that could change standards of care,” said Henar Hevia, Ph.D., Senior Director, EMEA Therapy Area Head, Oncology, Johnson & Johnson Innovative Medicine. “Our ambition is to translate our deep expertise in hematology into tangible progress in solid tumors, delivering therapies that not only extend survival but also preserve quality of life for patients and families.”
Among the studies to be presented are first results from a Phase 1b/2 trial of subcutaneous amivantamab for patients with recurrent or metastatic head and neck cancer who have progressed after immunotherapy and chemotherapy. Additional studies include results from trials involving patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, updates on once-monthly dosing of subcutaneous amivantamab, and analyses of new investigational treatments in prostate and bladder cancers.
The company will also present findings from its research on pasritamig, a bispecific T-cell-engaging antibody for metastatic castration-resistant prostate cancer, which has received Fast Track designation from the U.S. Food and Drug Administration.
Other studies will focus on investigational therapies such as the gemcitabine intravesical system for muscle-invasive bladder cancer, as well as ongoing research into combination treatments like niraparib and abiraterone acetate, which received approval from both European and U.S. regulatory agencies in 2023 for BRCA-mutated metastatic castration-resistant prostate cancer.
Johnson & Johnson's pipeline includes several products at different stages of development or approval, including erdafitinib, an oral FGFR kinase inhibitor that received accelerated approval from the U.S. FDA in 2019 for certain patients with urothelial carcinoma and EC approval in August 2024. More information about companion diagnostics for erdafitinib can be found at http://www.fda.gov/CompanionDiagnostics.
Apalutamide, another drug developed by the company, has been approved for patients with both non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer since 2018 and 2019, respectively.
The company notes that some of these treatments remain investigational and are subject to ongoing clinical trials. Johnson & Johnson cautions that statements about product development and future benefits are forward-looking and subject to risks described in its filings with the Securities and Exchange Commission.
More information about Johnson & Johnson’s work can be found at https://www.jnj.com/ and www.innovativemedicine.jnj.com.